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tion. Its acyl transferase activity cross-links certain proteins, among them transcription factors were
described. We show here that the TG2 inhibitor KCC009 reversed resistance to tumor necrosis factor-
related apoptosis-inducing factor (TRAIL) in lung cancer cells. Sensitization required upregulation of
death receptor 5 (DR5) but not of death receptor 4. Upregulation of DR5 involved the ﬁrst intron of
the DR5 gene albeit it was independent from p53 and nuclear factor kappa B. In conclusion, inhibi-
tion of tissue transglutaminase provides an interesting strategy for sensitization to TRAIL-induced
apoptosis in p53-deﬁcient lung cancer cells.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the leading cause of cancer death in the United
States among both, men and women. The projected number of
new lung cancer cases in 2008 in the United States was 215 020,
accounting for 15% of all new cancer cases and for 29% of all cancer
deaths. In fact, more people die each year from lung cancer than
from breast, colorectal, prostate, and ovarian malignancies com-
bined [1].
A potential new anticancer drug provides the cytokine tumor
necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL).
TRAIL is closely related to TNF-a and FasL, members of the tumor
necrosis factor family. TRAIL induces apoptosis via interacting with
death receptor 4 (DR4, TRAIL-R1) and death receptor 5 (DR5,
TRAIL-R2) leading to the formation of the death-inducing signalingchemical Societies. Published by E
AIL, tumor necrosis factor-
eceptor 4 (5); NF-jB, nuclear
Research, University of Bern,
1 31 632 0454.complex (DISC) with subsequent binding of caspase-8 (FLICE).
Recruitment of caspase-8 to the DISC activates its proteolytic prop-
erties, which initiates a cascade of protease such as caspase-3, pro-
moting the cleavage of death substrates and ﬁnally resulting in
apoptosis [2]. Different studies have shown that TRAIL induce
apoptosis only in tumor but not in normal cells [3,4] suggesting
that TRAIL can be used as a new cancer-selective treatment option.
One problem for the use of TRAIL as anticancer agent is provided by
the fact that about half of tumor cells are resistant to TRAIL-
induced apoptosis. Consequently, there is a need for strategies to
sensitize cancer cells but not normal cells to TRAIL-mediated cell
death.
In the present study we show that tissue transglutaminase
(TG2, tTG) might provide an interesting target how to sensitize
lung cancer cells to TRAIL-induced apoptosis. TG2 belongs to a
family of transglutaminase proteins that cross-links and thereby
stabilizes proteins by a Ca2+-dependent formation of amide bounds
between glutamine side chains and e-amino groups of lysine
residues. In addition to the acyl transferase activity, TG2 has a
GTP hydrolyzing activity which is Ca2+-independent [5,6]. Expres-
sion of TG2 was shown to be elevated in various forms of cancer.lsevier B.V. All rights reserved.
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TG2 enzymatic activity reversed chemoresistance in cancer cells
[7,8].TRAIL  -                  +           -                  +               +
KCC009 -           -                   +                 +                -








































Fig. 1. Cell death in lung cancer cells induced by combined treatment with TRAIL
and the TG2 inhibitor KCC009. Different lung cancer cell lines were treated with
100 ng/ml TRAIL and/or 500 lM KCC009 for 48 h. Cell death was assessed by PI
staining followed by ﬂow cytometry. Data represent the mean of at least three
independent experiments in duplicates ± S.D. ***P < 0.001 vs. TRAIL.2. Materials and methods
2.1. Reagents and cells
Soluble, non-trimerized TRAIL was kindly provided by Genen-
tech (South San Francisco, CA). KCC009 was a kind gift of Alvine
Pharmaceuticals, Inc. (Palo Alto, CA). The human lung cancer cell
lines A549, Calu1 and H1299 (American Type Culture Collection)
were maintained as described before [9].
2.2. Apoptosis assays
Cell death was evaluated by the assessment of propidium iodide
uptake as described before [9]. Caspase-3 and caspase-9 activities
were determined essentially as described previously [10] using
DEVD-amc and LEHD-afc as substrates.
2.3. Immunoblot analysis
Fifty micrograms of protein were separated by polyacrylamide
gel electrophoresis. The following antibodies were used: PARP
(clone C-2-10, Alexis), cleaved lamin A (Cell Signaling Technology,
Inc.) transglutaminase II (clone CUB 7402, Lab Vision Corp.) and a-
tubulin (Sigma).
2.4. Determination of TRAIL receptor expression
Protein expression of DR4 and DR5 were determined as de-
scribed before [9]. TRAIl receptor antibodies clones DR4-M271
and DR5-M413 were kindly supplied by Immunex Corp. (Seattle,
WA)
2.5. Quantitative real-time RT-PCR
Total RNA was isolated using the GenElute™ kit (Sigma) and
cDNA was synthesized. Assay-on-Demand probes for the TaqMan
real-time PCR system for DR4 and DR5 and the internal housekeep-
ing control-gene, GAPDH, were obtained from Applied Biosystems.
2.6. Transfection with siRNA
Cells were transfected with 1 lg small interfering RNA (siRNA)
(Qiagen) by using 2 ll Dharmafect™ reagent (Dharmacon). All siR-
NAs were described before [7,11] 24 h after transfection, cells were
stimulated for 48 h with 500 lM KCC009 and/or 100 ng/ml TRAIL.
2.7. Transfection with reporter plasmids and luciferase assay
Luciferase reporter plasmids (for details see [12–14]) were
transfected using DharmafectDUO reagent (Dharmacon). Eight
hours after transfection cells were treated with 500 lM KCC009
for 40 h before harvesting for luciferase assay. Fireﬂy luciferase
and Renilla luciferase assays were performed using the Dual-Lucif-
erase Reporter Assay System (Promega).
2.8. Statistical analysis
If not stated otherwise data were subjected to one- or two-
way ANOVA using GraphPad Prism 4.03. Differences between
experimental groups were determined by Bonferroni post-hoctest. Differences were considered statistically signiﬁcant at P val-
ues <0.05.3. Results
3.1. Inhibition of TG2 sensitizes lung cancer cells to TRAIL-induced
apoptosis
We ﬁrst analysed whether lung cancer cells can be sensitized to
TRAIL-induced apoptosis by pharmacological inhibition of TG2
activity. We used KCC009 which was demonstrated to be a highly
speciﬁc and irreversible inhibitor of TG2 acyl transferase activity
[15]. Initial experiments showed cytotoxicity of KCC009 alone in
concentrations exceeding 500 lM (data not shown). Therefore,
500 lM of KCC009 was used for further experiments. Although
treatment of the three TRAIL-resistant lung cancer cell lines (Calu1,
H1299 and A549) with KCC009 alone for 48 h was not toxic, the
combination of KCC009 and TRAIL induced considerable cell death
suggesting that TG2 acyl transferase activity served as an inhibitor
of TRAIL-induced apoptosis (Fig. 1). To prove whether this effect
was in fact related to TG2, we abolished the expression level of





























Fig. 2. Silencing of TG2 by siRNA lead to a signiﬁcant increase in TRAIL-mediated cell death. Calu1 cells were transfected with TG2 speciﬁc siRNA or non-silencing control
siRNA. (A) siRNA-mediated knockdown of TG2 was conﬁrmed by Western blot analysis 24 or 48 h after transfection. (B) Transfected cells were treated with 100 ng/ml TRAIL;

























TRAIL  - + - + +
KCC009 - - + + -
DMSO  - - - - +
TRAIL          -      + -      +     +
KCC009          -       - +     +       -



























Fig. 3. Activation of caspases in lung cancer cells treated with the combination of
TRAIL and KCC009. Calu1 cells were treated for 24 h with TRAIL in the presence or
absence of KCC009 and subsequently harvested in lysis buffer. Caspase-3 and -9
activities were measured by determination of (A) hydrolysis of DEVD-amc and (B)
cleavage of LEHD-afc, respectively. Data of three independent experiments are
expressed as mean ± S.D. **P < 0.01 and ***P < 0.001 vs. TRAIL. (C) Cleavage of the
caspase substrates lamin A and PARP were determined by Western blot analysis.
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more susceptible to TRAIL-induced apoptosis (Fig. 2A and B).
3.2. Cell death induced by combined treatment with KCC009 and TRAIL
reveals typical hallmarks of apoptosis
We further analysed apoptosis-related events induced by the
combination of the TG2 inhibitor KCC009 and TRAIL. While
KCC009 and TRAIL alone were not able to trigger caspase-3 activity,
the combination of both substances induced remarkable caspase-3
activation (Fig. 3A). Similar results were demonstrated for caspase-
9 (Fig. 3B) suggesting an involvement of the mitochondrial type II
apoptotic pathway. In addition, cleavage of the so called death sub-
strates lamin A and PARP were found in cells treated with the com-
bination of KCC009 and TRAIL but not in cells treated with either
agent alone (Fig. 3C).
3.3. KCC009 increases cell surface expression and mRNA of DR5, but
not of DR4
Next we asked what molecular mechanism might be responsi-
ble for KCC009-mediated sensitization to TRAIL-induced apoptosis.
Therefore, we measured changes in DR4 and DR5 expression after
treatment with KCC009. For DR4, no changes in expression neither
at the protein nor at the mRNA level were determined. In contrast
to DR4, cell surface expression of DR5 was markedly increased in
cells treated with KCC009. This effect was due to an augmentation
of DR5 transcription demonstrated by higher mRNA level (Fig. 4A
and B). However, despite lung cancer cells were also sensitized to
TRAIL-induced apoptosis by siRNA-mediated knockdown of TG2,
we were not able to observe increased DR5 expression in these
cells (data not shown).
3.4. KCC009-mediated sensitization to TRAIL-induced apoptosis
depends on upregulation of DR5
Given higher expression levels of DR5 in KCC009 treated lung
cancer cells; we next determined whether this effect was essential
for sensitization to TRAIL-induced apoptosis. Therefore we blocked
receptor upregulation using siRNA against DR4 and DR5. Subse-
quently, cells were treated with KCC009 and TRAIL followed by
the measurement of cell death. As expected, inhibition of DR4
upregulation demonstrated no inﬂuence on cell death induced by
the combination of KCC009 and TRAIL. Instead, blockage of DR5
upregulation signiﬁcantly diminished the extent of apoptosis pro-
posing that upregulation of DR5 plays an essential role in KCC009-






























































Fig. 4. KCC009 increases expression level of DR5 but not of DR4. (A) Calu1 cells were treated for 24 h with 500 lM KCC009, immunostained and then analyzed for TRAIL
receptor expression. Representative data of three independent experiments. (B) Cells were treated with 500 lM KCC009 for the indicated time points; DR4 and DR5 mRNA























Fig. 5. Elevated DR5 expression accounts for TRAIL-sensitizing effects in lung
cancer cells. KCC009-mediated upregulation of DR5 was selectively blocked using
siRNA followed by stimulation with TRAIL and KCC009 for 48 h. Mean ± S.D. of three
independent experiments in duplicates. ***P < 0.001 vs. control siRNA.















Luciferase activity (fold induction)
Fig. 6. KCC009-mediated activation of DR5 genomic promoter region. H1299 cells
were transfected with luciferase reporter plasmids containing 50-deletion mutants
of human DR5 promoter as well as constructs including the DR5 promoter plus the
ﬁrst intronic region. After 8 h cells were washed and treated with solvent or 500 lM
KCC009 for 40 h before harvesting for luciferase assay.
2870 M. Frese-Schaper et al. / FEBS Letters 584 (2010) 2867–28713.5. KCC009-mediated upregulation of DR5 requires the ﬁrst intron of
the DR5 genomic promoter region
To further evaluate the mechanism how KCC009 upregulates
the expression of DR5 we expressed luciferase reporter plasmids
with deletion mutants of the DR5 promoter as well as constructs
containing the full length promoter plus part of the ﬁrst intronic
region of the DR5 gene. Construction of these plasmids has been
described before [12–14]. Surprisingly, none of the plasmids
containing the full length promoter region (pDR5 PF) as well as
50-deletions mutants of this construct demonstrated increasedluciferase activity after stimulation with KCC009. Only the two
plasmids containing the full length DR5 promoter region and parts
of the ﬁrst intron (pDR5/MluI and pDR5/mtNF-jB) showed an
impressive activation of luciferase activity (Fig. 6). Since the only
difference between pDR5/MluI and pDR5/mtNF-jB is a mutated
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it suggests that NF-jB does not critically contribute to the en-
hanced expression of DR5 induced by KCC009.4. Discussion
The data presented here suggest that application of the TG2
inhibitor KCC009 in combination with TRAIL provides a new strat-
egy to sensitize lung cancer cells to TRAIL-induced apoptosis. The
pivotal question was on how inhibition of TG2 activity reverses
resistance to TRAIL. In glioblastoma the involvement of protein ki-
nase B (Akt) in KCC009-mediated reversal of chemoresistance was
demonstrated [16]. However, in ovarian cancer protein kinase B
was excluded to be responsible for KCC009-induced sensitization
to chemotherapy; instead NF-jB was shown to be involved [17].
Our data obtained in lung cancer cells propose a new mechanism
how KCC009 reverses resistance to apoptosis. It is known that
TG2 catalyzes cross-linking of certain intracellular proteins. Hence
it might conceivable that in non-treated lung cancer cells tran-
scriptions factors responsible for regulation of DR5 expression
are inactive through TG2-mediated cross-linking. In turn, treat-
ment of lung cancer cells with the TG2 inhibitor KCC009 pre-
vented cross-linking and subsequently, DR5 transcription was
activated. TG2-initiated cross-linking and subsequent inactivation
of transcription factors has been shown before for Sp1 in liver
cells [18].
Which transcription factors are involved in KCC009-mediated
upregulation of DR5 remains unsolved yet. Our data demonstrated
the requirement for the ﬁrst intronic region of the DR5 gene. The
need of the ﬁrst intron and their p53 and NF-jB binding sites in
DR5 upregulation was shown before for the TRAIL-sensitizing
agents etoposide and the proteasome inhibitor MG132 [13,19]. In
our experimental setup mutation in the NF-jB binding site did
not abrogate KCC009-induced promoter activity suggesting that
NF-jB is not critically involved DR5 upregulation. Furthermore,
we were able to exclude p53 to play a role in DR5 upregulation
since H1299 cells are null-mutants of p53 [20] but were sensitized
by KCC009 nonetheless. Of note, in H1299 cells the p53-dependent
proteasome inhibitor MG132 was unable to induce DR5 expression
and consequently did not sensitize to TRAIL-induced apoptosis
[19]. Since lung cancer cells are most frequently mutated in p53
[21], TRAIL-sensitizing agents acting independently from p53 as
shown for KCC009 might provide an important advantage for this
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